Perrigo
PRGOMarket price data through September 10, 2026.
Performance
Sep 2021 – Sep 2026
Track record
How this pick has done since Benson first called it.
- Benson Return
- 0%
- How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
- First pick price
- ~$14
- Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
- Tracking since
- September 2026
- The month this stock first became a Benson pick.
- Tracking duration
- 0 months
- How long Benson has been tracking this pick.
About Perrigo
Perrigo makes the store brand version of the medicine you already buy, the generic Tylenol or Sudafed sitting next to the name brand at Walmart or CVS. It is one of the largest makers of these private label self care products in the world, selling in about 30 countries and bringing in more than 4 billion dollars a year.
The case for and against
Both sides of the story, in plain English.
- Dirt Cheap Stock
Perrigo trades at roughly 5 times next year's earnings, a fraction of what a normal healthcare company trades for. The stock has already been beaten down about 59 percent over the past year, so a lot of bad news is already priced in, and the company just sold its Dermacosmetics business for 359 million dollars to pay down debt.
- Huge Dividend, Long Track Record
Perrigo has raised its dividend every year for 22 years straight and currently pays out a yield above 10 percent. Management used most of the proceeds from its recent divestiture to cut debt instead of touching the dividend, showing where their priorities are.
- Sales Keep Shrinking
Revenue fell about 3 percent in the most recent quarter and is on pace to fall as much as 5.5 percent for the full year. Retailers pulled back on ordering and shoppers bought less cold and allergy medicine, and it is not yet clear when that turns around.
- Heavy Debt Load and a Shaky Boardroom
The company carries about 3.3 billion dollars in debt, roughly four times its yearly cash profits, and just wrote down 1.6 billion dollars in goodwill over two straight quarters. On top of that, the CEO was pushed out this summer for a conduct violation, leaving an interim leader in charge while the board searches for a permanent replacement.
Other companies we track
How to read this page
This automated research summary uses Financial Modeling Prep market data through 2026-09-10. Model signals, scores, and risk labels can change and may be incomplete or wrong.
Want Benson to watch PRGO for you?
Get the app to follow every Benson pick live — and let Benson do the research for you.
Download on the App Store
Download Android app